Assembling Ligands In Situ Using Bioorthogonal Boronate Ester Synthesis  by Shin, Sung Bin Y. et al.
Chemistry & Biology
Brief CommunicationAssembling Ligands In Situ
Using Bioorthogonal Boronate Ester Synthesis
Sung Bin Y. Shin,1,3 Ramiro D. Almeida,1,3 Guillermo Gerona-Navarro,1,3 Clay Bracken,2 and Samie R. Jaffrey1,*
1Department of Pharmacology
2Department of Biochemistry
Weill Medical College, Cornell University, New York, NY 10065, USA
3These authors contributed equally to this work
*Correspondence: srj2003@med.cornell.edu
DOI 10.1016/j.chembiol.2010.09.008SUMMARY
Many molecules that could manipulate cellular
function are not practical due to their large size and
concomitant undesirable pharmocokinetic proper-
ties. Here, we describe a bioorthogonal, highly stable
boronate ester (HiSBE) synthesis and use this reac-
tion to synthesize a biologically active molecule
from smaller precursors in a physiological context.
The rapid rate of HiSBE synthesis suggests that it
may be useful for assembling a wide variety of bio-
logically active molecules in physiological solutions.
INTRODUCTION
Synthetic reactions are typically performed using catalysts,
temperatures, and organic solvents that are not compatible
with living cells. However, certain chemical reactions can occur
in biological solutions and physiological conditions, and are not
affected by the complex mixture of small molecules and proteins
that are characteristic of biological solutions. These reactions
are referred to as ‘‘bioorthogonal,’’ and provide the opportunity
to probe cellular function with organic synthesis (Prescher and
Bertozzi, 2005). Bioorthogonal reaction strategies involve pre-
synthesized nonnative chemical moieties that typically perform
the final synthetic step in the cellular environment.
Certain reactions have been shown to exhibit bioorthogonal-
ity, such as copper-free ‘‘click’’ chemistry (Baskin et al., 2007),
and the Staudinger ligation (Saxon and Bertozzi, 2000). These
reactions are distinct from bioconjugation reactions, such as
reactions of labeling agents with cysteine or tyrosine (Joshi
et al., 2004; Sletten and Bertozzi, 2009), or the formation of
oximes by reaction of aminoxy moieties with aldehydes or
ketones (Sletten and Bertozzi, 2009), since the nonnative
chemical moieties involved in bioorthogonal reactions are non-
perturbing to chemical functionalities found in living systems
and demonstrate high selectivity (Prescher and Bertozzi, 2005;
Sletten and Bertozzi, 2009). For example, copper-free click
chemistry involves the reaction of an azide and an alkyne to
form a triazole in a [3 + 2] cycloaddition (Baskin et al., 2007).
The reactivity of the alkyne is promoted by ring strain and can
be enhanced by halogen substitution, resulting in rapid reaction
rates and an elimination of the need for copper, which is other-Chemistry & Biology 17, 1171–117wise required for this class of click reactions (Baskin et al.,
2007; Codelli et al., 2008). Bioorthogonal reactions have been
used to develop chemical reporters for labeling and visualizing
biomolecules in living cells (Prescher and Bertozzi, 2005). In
these reactions, bioorthogonal functional groups are metaboli-
cally incorporated into biomolecules, and then probes that
contain reactive moieties are covalently coupled by a sponta-
neous bioorthogonal reaction.
Current bioorthogonal reactions have limitations that affect
their use. In the case of the Staudinger ligation, slow reaction
rates and oxidation of reactants affect its usefulness (Lin et al.,
2005). Although the copper-free click reaction exhibits signifi-
cantly higher reaction kinetics (9.0 3 102 M-1 s-1) (Baskin
et al., 2007; Codelli et al., 2008), the reaction rates are still slow
relative to the timescales used for biological experiments, and
the availability of additional bioorthogonal reactions would
provide additional versatility for chemical reactions in living cells.
Because of the limitations of existing bioorthogonal reactions,
wesought to identifywhetherotherpreviouslydescribed reactions
could be used for bioorthogonal chemistry. Phenylboronic acid
(PBA) interacts with D-glucose to form boronate esters that are
readily hydrolyzed in water (Ferrier et al., 1965). However, Stolo-
witz and colleagues recently showed that PBA interacts with sali-
cylhydoxamic acid (SHA) to form considerably more stable boro-
nate esters (Stolowitz et al., 2001). The bioconjugate reactions of
PBA and SHA have been used to purify biomolecules such as
proteins and nucleic acids modified with SHA residues (Stolowitz
et al., 2001). Unlike D-glucose, which interacts with boronic acid
through vicinal diols (Ferrier et al., 1965), SHA interacts with
boronic acid through both an oxygen and a nitrogen, which
may account for the increased stability (Stolowitz et al., 2001).
The boron-nitrogen bond has both ionic and covalent character
(Plumley and Evanseck, 2007). These boronate esters exhibit
pH-dependent hydrolysis, with instability at low pHs (pH <5)
(Stolowitz et al., 2001). Based on the increased resistanceof these
boronate esters to hydrolysis at neutral pHs, we refer to this reac-
tion as highly stable boronate ester (HiSBE) synthesis. Due to its
success inbioconjugation reactions,weconsidered thepossibility
that HiSBE chemistry would exhibit bioorthogonality.
RESULTS AND DISCUSSION
HiSBE Synthesis between SHA and PBA
We first asked if the HiSBE reaction was affected by biological
nucleophiles. To measure boronate ester formation between6, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1171
Figure 1. HiSBE Synthesis Is Facile and Orthogonal to Common
Biological Nucleophiles
(A) Time-dependent boronate ester formation between SHA and PBA immobi-
lized on agarose in 100 mM phosphate buffer at pH 7.4. Reaction solutions
containing 6mMSHA (0.0036 mmol, 0.6 ml) were incubated with PBA agarose
(0.1 ml, 0.002 mmol of immobilized PBA). The SHA concentration in the
supernatant was quantified by absorption spectrophotometry at 214 nm.
(B) The efficiency of HiSBE synthesis in the presence of common biological
nucleophiles. Reaction solutions containing 6 mM SHA (0.0036 mmol,
0.6 ml) in 6% DMEM/100 mM phosphate buffer at the indicated pH and with
the indicated nucleophiles were incubated with PBA agarose (0.1 ml,
0.002 mmol of immobilized PBA) for 5 min. After incubation, the resin was
washed to remove uncomplexed SHA, and the complexed SHA was eluted
with 100 mM phosphate buffer at pH 4.5. Eluted SHA was quantified by
absorption spectrophotometry at 214 nm.
(C) Kinetic measurement of 0.1 mM SHA with 0.1, 0.2, and 0.5 mM PBA in
100 mM phosphate buffer at pH 7.4. The reaction rates were modeled
after third-order reaction kinetics and were determined by plotting 1/(([SHA]-
[SHA]f) 3 [PBA]0)) versus time. The slopes were used to approximate the
rate constants. k = (7.01 ± 2.04) 3 106 M-2s-1.
See also Figure S1.
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agarose at pH 7.4. After incubation, the complexed SHA was
eluted with low pH buffer (pH 4.5), which hydrolyzes SHA-PBA
complexes (Stolowitz et al., 2001). Eluted SHA was quantified
by absorption spectrophotometry. A linear increase in boronate
ester formation was observed during the first 1min of incubation,
with saturation observed after 5 min (Figure 1A).
To determine the effect of common biological nucleophiles
such as serine, cysteine or lysine, as well as D-glucose, on
HiSBE synthesis, we measured the effect of these compounds
on boronate ester synthesis measured at 5 min. None of these
treatments significantly reduced the ester formation (Figure 1B).1172 Chemistry & Biology 17, 1171–1176, November 24, 2010 ª2010Similarly, tissue culture media, which contains diverse small
molecule cofactors, amino acids, and ions found in biological
solutions, did not affect the interaction of PBA and SHA (Fig-
ure 1B). Together, these data indicate that the reaction of
PBA and SHA is not affected by molecules commonly found in
biological solutions.
We measured the association constants of PBA and SHA. The
coordination state of the boron nucleus changes from trigonal to
tertrahedral after complexation with SHA, which is detected by
the chemical shift of boron in 11B-NMR (Beachell and Beistel,
1964; Stolowitz et al., 2001). To monitor association, we
incubated 10 mM PBA with varying concentrations of SHA in
phosphate buffer. The observed association constant was
17,800M-1 at pH 7.4 and 4M-1 at pH 4.5, indicating that the com-
plexed form is highly favored at physiological pH. To measure
the association rate constant, we used UV spectrophotometry
to measure the reaction of SHA with PBA with respect to time.
Based on the linear relationship demonstrated in rate versus
[SHA]2[PBA] (see Figure S1 available online), the reaction of
SHA and PBA was modeled with a third order rate constant.
The plot of 1/([SHA][PBA]0) versus time was used to determine
the kinetic rate of (7.01 ± 2.04) 3 106 M-2 s-1 (Figure 1C). These
data indicate that this reaction occurs considerably faster than
previously described bioorthogonal chemical reactions.
Assembly of Dimeric c-Mpl via HiSBE
We next wanted to determine if boronate ester synthesis can
occur in a physiologically relevant setting. To test the bioortho-
gonality of this reaction, we sought to generate biologically
active molecules in situ using HiSBE synthesis. Numerous
receptors are activated by ligands which bind and dimerize
their cognate receptors (Heldin, 1995). In the case of the throm-
bopoeitin (TPO) receptor c-Mpl, receptor dimerization and
activation is triggered by binding TPO (Cwirla et al., 1997). Pep-
tide ligands to c-Mpl, such as IEGPTLRQWLAARA, have been
identified, but due to their monomeric nature exhibit only weak
agonist activity (Cwirla et al., 1997). However, dimeric forms
of the peptide act as agonists of the receptor. In one case,
a c-Mpl-activating pseudosymmetric dimer was prepared on
a lysine scaffold: the COOH terminus of one IEGPTLRQWLAARA
was coupled to the 3-amine of the lysine, while the COOH
terminus of another IEGPTLRQWLAARA was coupled to the
a-amine of the lysine via a linker, resulting in a potent c-Mpl
agonist (Cwirla et al., 1997).
To assess the bioorthogonality of HiSBE synthesis, we
decided to determine if a dimeric c-Mpl agonist could be synthe-
sized in situ, and if the synthesized compound could lead to the
activation of c-Mpl signaling in cells. Rather than using a lysine
linker, we decided to use a ‘‘dimerizer’’ comprising two SHA
moieties connected by a linker (Figure 2A). This dimerizer is
expected to generate a dimeric c-Mpl ligand by interacting
with two IEGPTLRQWLAARA, each synthesized with a PBA
appended to the COOH terminus. We reasoned that the
c-Mpl-binding peptide would exhibit increased agonist activity
if it became dimerized upon application to cells which contained
the dimerizer.
We first confirmed that this dimerizer could simultaneously
bind two PBA molecules. The dimerizer was titrated into a solu-
tion of 10 mM PBA in 100 mM phosphate buffer at pH 7.4, andElsevier Ltd All rights reserved
Figure 2. Assembly of PBA on a Dimerizing Scaffold
(A) Synthetic scheme of ‘‘dimerizer’’ synthesis.
(B) Titration of a dimerizer reveals stoichiometric complexation with PBA.
11B-NMR spectra of 10 mM PBA and 0, 2.5, 5, 10, and 20 mM of the dimerizer
in 6% DMSO-d6/ 100 mM of deuterated phosphate buffer in D2O (pD = 7.4).
PBA is largely complexed when present at a 2:1 ratio with dimerizer, as
evidenced by the appearance of the tetrahedral coordination state of boron
(6.7 ppm), and loss of the free PBA, which exhibits tetrahedral boron coordina-
tion geometry (30.8 ppm).
(C) 1H NMR spectra of dimerizer and PBA-modified c-Mpl-activating peptide
at various relative concentrations in DMF-d7. The inset shows the structure
of one of the two SHA present on the dimerizer. The hydroxamate O-H proton
is labeled (A) and this proton does not participate in the complex formation.
The hydroxamate N-H proton is labeled (B) and this proton is removed
when the nitrogen atom forms a dative coordinate bond with boron in the
peptide. The numbers below peaks (A) and (B) represent the relative area
under each peak. With increasing concentrations of the peptide, the area
under peak (B) is diminished, indicating the complex formation.
The peak assignments for protons (A) and (B) were made based on the
previous reports (Garcia et al., 2007).
See also Figure S2.
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appearance of the tetrahedral boron hybridization state as
measured by 11B-NMR. At a 2:1 PBA:dimerizer ratio, the boron
was essentially completely observed to be in the tetragedral
configuration (Figure 2B), indicating that each dimerizer was
simultaneously complexed to two PBA molecules.Chemistry & Biology 17, 1171–117We next addressed whether the dimerizer could recruit two
peptides to form a dimeric peptide ligand. When the PBAmoiety
on the peptide forms a complex with the SHA moiety on the
dimerizer, the hydroxamate NH proton is removed and a N-B
bond is formed. The formation of dimeric c-Mpl ligand was
demonstrated by the complete disappearance of the hydroxa-
mate NH proton NMR signal in a 2:1 mixture of PBA-modified
IEGPTLRQWLAARA and dimerizer (Figure 2C). We next sought
to determine themass of the complex. StandardMS approaches
were not successful due to hydrolysis of the boronate ester by
the acidic buffers used in ESI and the acidic matrices commonly
used in MALDI. We therefore measured the size using 2D
DOSY-NMR. The molecular size of the 2:1 ratio of PBA-modified
IEGPTLRQWLAARA and the dimerizer measured by 2D DOSY
NMR was consistent with the expected hydrodynamic size of a
complex composedof twopeptidemolecules andasingledimer-
izer (Figure S3A). Together, these data indicate that the dimerizer
recruits two peptides to form a dimeric peptide complex.
Formation of a c-Mpl-Activating Ligand In Situ
We next addressed whether HiSBE chemistry could be used to
synthesize c-Mpl agonists in tissue culture. Consistent with
previous studies (Kaushansky et al., 1994; Yamada et al.,
1995), BaF3-cMpl cells, which overexpress c-Mpl, exhibit in-
creased p42/44 MAPK phosphorylation in response to TPO
(5 ng/ml), as measured by anti-p42/44 MAPK western blotting
(Figures 3A and 3B). Application of the PBA-modified
IEGPTLRQWLAARA also increased p42/44 MAPK activity,
consistent with earlier data showing that this monomeric peptide
exhibits weak agonist activity (Cwirla et al., 1997). However,
inclusion of the dimerizer along with the peptide resulted in a
doubling of p42/44 MAPK levels (Figures 3A and 3B). This effect
wasmediated by c-Mpl, as BaF3 cells that did not express c-Mpl
did not exhibit an increase in p42/44MAPK upon TPO or peptide
treatments, but remained responsive to IL-3, a cytokine that
activates p42/44 MAPK through an independent pathway (Pala-
cios and Steinmetz, 1985; Figure 3C). Furthermore, this effect
was dependent on the dimerizer, as SHA, which functions as a
monomeric control, did not elicit a statistically significant
increase in p42/44 MAPK relative to peptide alone (Figures 3D
and 3E). Last, we examined the effect of a control peptide that,
when dimerized, activates an unrelated receptor, TrkB (O’Leary
and Hughes, 2003). Application of either the control peptide
alone or the peptide in the presence of the dimerizer resulted
in no detectable activation of p42/44 MAPK (Figure 3F).
Together, these data indicate that the dimerizer and the peptide
react to form a c-Mpl-activating ligand in tissue culture media in
the presence of cells.
To further examine the bioorthogonality of HiSBE synthesis, we
assessed the effects of the reactants on cell proliferation and
viability. Neither the dimerizer or the PBA-modified peptide
reduced cell proliferation as measured by the MTT viability assay
(Figure 3B), consistentwith previous data suggesting the compat-
ibility of the boronic acid and salicylhydroxamic acid pharmaco-
phores in livingsystems (Barnicoat etal., 1981;Dennisetal., 2003).
Our data suggest that HiSBE synthesis can be used to
assemble bioactive compounds in a physiologic setting.Multiva-
lent presentation of receptor ligands is a well-established
approach to switch inactive or relatively inactive ligands to6, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1173
Figure 3. Synthesis of an Active c-Mpl
Ligand In Situ
(A–F) BaF3-cMpl and BaF3-WT (parental) cells
were transferred to media lacking IL-3, and
cultured for 5 hr. The cells were then stimulated
with the indicated compounds for 10 min at 37C
and analyzed by immunoblot against phospho-
p44/42 MAPK (upper panel) and total p44/42
MAPK (lower panel). In each experimental
condition, the immunoreactivity obtained was
calculated as a percentage of the total signal
obtained. Data are presented as mean ± SEM
of four independent experiments and each immu-
noblot is representative of four independent
experiments.
(A) The agonist activity of the c-Mpl peptide is
enhanced by the dimerizer. BaF3-cMpl cells
were stimulated with TPO and IL-3, resulting in
enhanced phospho-p44/42 MAPK levels as
measured by western blotting. The PBA-modified
c-Mpl peptide (P) is a weak agonist of c-Mpl
signaling, which is enhanced by treatment with
the dimerizer (D). The dimerizer does not exert
any agonist activity on its own.
(B) Quantification of results in (A). Groups were
compared using a one-way ANOVA and New-
man-Keuls post-test: **p < 0.001 (n = 4) of P alone
relative to P + D. Data are presented as mean ±
SEM of four independent experiments.
(C) The effects of peptide-dimer complexes are
mediated through c-Mpl. BaF3-WT cells, which
are the parental line for the BaF3-cMpl cells, do
not express c-Mpl. Under the same conditions
as (A), the c-Mpl peptide and the dimer fail to
activate c-Mpl signaling as assayed by phospho-
p44/42 MAPK western blotting.
(D) The c-Mpl-binding peptide is not significantly
activated by a monomerizer. SHA, a monomeric
control (M) to the dimerizer used in (A), was used
to form complexes with the PBA-modified c-Mpl
binding peptide. Treatment of cells with SHA along
with the c-Mpl peptide failed to significantly
increase phospho-p44/42 MAPK levels. These
data support the idea that the dimerizer induces
the formation of a dimeric complex which is the
most efficacious ligand to activate c-Mpl
signaling.
(E) Quantification of the results in (D). Groups were compared using a one-way ANOVA and Newman-Keuls post-test: n.s. = non significant (n = 4) of P alone
relative to P + M. Data are presented as mean ± SEM of four independent experiments.
(F) Activation of c-Mpl signaling requires a c-Mpl-binding peptide. When a PBA-modified peptide that targets TrkBwas used, no phospho-44/42MAPK activation
was detected with either the peptide alone or in conjunction with the dimerizer. These results suggest that activation of c-Mpl signaling is mediated by
a sequence-specific interaction with c-Mpl by a dimerized peptide.
See also Figure S3.
Chemistry & Biology
Bioorthogonal Boronate Ester Synthesisreceptor agonists (Fournel et al., 2005), and combinatorial
libraries of symmetric multivalent ligands as potential receptor
agonists have attracted considerable attention (Boger et al.,
1997). However, these molecules and molecules with similarly
high molecular weights are typically accompanied by poor
solubility or undesirable pharmacokinetics (Lipinski, 2000).
Synthesis of thesecompounds in situ provides apreviously unex-
plored avenue to alleviate some of these problems, providing
a strategy to facilitate the therapeutic use of multivalent ligands.
Although our focus is the design of dimeric and multimeric
receptor agonists that act on the cell surface, in situ ligand
assembly could also conceivably be used to synthesize mole-1174 Chemistry & Biology 17, 1171–1176, November 24, 2010 ª2010cules within cells. In this approach, at least two cell-permeable
molecules, one containing a PBA moiety and the other contain-
ing a SHA moiety would be applied to cells, allowing bioactive
complexes to form in the cytoplasm. This approach may enable
the formation of large and otherwise impermeable molecules to
accumulate and exert effects in cells.
Assembly of molecules in situ requires rapid reaction kinetics
in order to provide temporal control over ligand synthesis. One
prominent feature of HiSBE synthesis is its rapid reaction rate.
The copper-free click reaction utilizing difluorinated cyclooctyne
(DIFO) exhibits rate constants (Baskin et al., 2007; Codelli et al.,
2008; Lin et al., 2005) that are several orders ofmagnitude slowerElsevier Ltd All rights reserved
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synthesis suggests that bioorthogonal boronate ester formation
will be useful for temporally controlled, rapid assembly of
molecules in vivo. Another feature of HiSBE synthesis is that
the reaction is reversible by ester hydrolysis. This reversibility
allows HiSBE-linked molecules to be hydrolyzed to lower
molecular weight components, providing a route to temporally
control the duration of action of HiSBE-linked molecules.
Although the copper-free click reactions using DIFO exhibits
slower reaction kinetics compared with the HiSBE reaction, it
may also be suitable for in situ ligand synthesis, especially in
applications where a nonhydrolyzable product is desired.
Themajor application of bioorthogonal chemistry thus far is for
labeling biomolecules in vivo with reporter groups (Prescher and
Bertozzi, 2005). In these experiments, the cellular metabolic
machinery is exploited to incorporate bioorthogonal functional
groups within biological molecules. Reporter probes are then
covalently coupled to these functional groups by spontaneous
bioorthogonal reactions. Copper-free click chemistry has been
particularly useful for these reactions since alkynes and azides,
the bioorthogonal functional groups in this reaction, are relatively
small allowing modified glycans, lipids and amino acid precur-
sors to be readily incorporated into biomolecules (Prescher
and Bertozzi, 2005). HiSBE synthesis may also be suitable for
bioorthogonal chemical reporters. PBA moieties have been
swapped for aromatic rings in both nucleotides and amino acids,
resulting in only mild perturbations of structure (Lin et al., 2007;
Snyder et al., 1958). Additionally, HiSBE formation can easily
be conducted with linkers that contain multiple SHA moieties,
potentially leading to multivalent bioactive ligands. Combina-
tions of PBA-modified ligands and SHA linkers raise the exciting
possibility of rapidly generative diverse combinatorial libraries.
Also, HiSBE formation leads to products containing tetrahedral
boron coordination states, which can be imaged in living animals
by 11B-magnetic resonance imaging (Kabalka et al., 1988),
raising the possibility of monitoring bioorthogonal reactions
in vivo.
SIGNIFICANCE
Wedemonstrate that the reaction of phenyl boronic acid and
salicylhydroxamic acid, HiSBE synthesis, exhibits bioortho-
gonality, and unusually rapid reaction kinetics. HiSBE
synthesis leads to boronate esters that are acid labile, and
which therefore can produce products that are expected
to be biodegradable under cellular conditions. Because of
the rapid reaction kinetics of HiSBE synthesis, we show
that this reaction can be used to generate bioactive
compounds from relatively inert precursors. Assembling
ligands in situ using bioorthogonal chemistry provides a
strategy to bypass problems of membrane permeability
and poor pharmacokinetics of many high molecular weight
compounds by allowing these compounds to be formed in
a cellular context.
EXPERIMENTAL PROCEDURES
Details of experimental procedures can be found in the Supplemental
Experimental Procedures.Chemistry & Biology 17, 1171–117SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at doi:10.1016/j.
chembiol.2010.09.008.
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